

EQUITY RESEARCH

KALEON
 RESULTS REVIEW

BUY

TP 5.5€

Up/Downside: 31%

A Solid First Release - Revenues 2025

Kaleon's first post-IPO publication confirms a solid growth trajectory, fully in line with our expectations, with 2025 revenue reaching €23.2m, up +6.8% versus 2024 (+9.2% on a like-for-like basis). This performance provides the first tangible indication of the company's potential, following the ongoing renovation and expansion works across the Borromean Islands and Villa Pallavicino.

H2 came in particularly strong, posting +7.6% yoy growth. Full-year momentum was mainly driven by the ticketing segment, which accounts for 76% of total revenue and delivered +10% growth vs 2024. This performance reflects both pricing effects and the success of combined tickets – with the 'Isola Bella + Isola Madre' offer now ranking as the second best-selling ticket. The food & beverage segment (14% of total revenue) also maintained a solid pace, up +12% yoy.

Hospitality and retail saw more moderate growth, consistent with their still-early deployment phase. Hospitality, however, is expected to ramp up meaningfully from 2027 onwards, supported by the opening of new rooms at Villa Pallavicino and the renovation of two buildings in Stresa.

Isola Bella, which represents 58% of consolidated revenue, delivered an excellent performance with revenues up +11%, including a price effect we estimate in the mid-single-digit range. Also noteworthy is the initial contribution from the Castelli di Cannero, which opened to the public in late June 2025 after renovation and added €0.3m to revenue.

The publication is fully in line with our initial estimates and confirms the attractive potential of Kaleon's growth trajectory. Considering ongoing expansions – notably in food & beverage and hospitality – the rollout of dynamic pricing, and a price effect estimated at 3–4% per year, we forecast 2024–2029e organic revenue growth of 8.8% CAGR. Additional upside could come from the potential management of third-party sites, with more details expected at the FY 2025 results release.

From a valuation standpoint, the stock is currently trading at 7.3x–6.5x 2026e–2027e EV/EBITDA, implying a 15–20% discount versus our peer group, despite Kaleon exhibiting stronger organic growth and a particularly robust cash-generation profile. These elements support our positive view on the name.

We therefore reiterate our BUY rating with a target price of €5.5.

TP ICAP Midcap Estimates	12/24	12/25e	12/26e	12/27e	Valuation Ratio	12/25e	12/26e	12/27e
Sales (m €)	21.7	23.2	26.1	28.6	EV/Sales	2.3	2.1	1.8
Current Op Inc (m €)	2.9	3.5	4.6	5.3	EV/EBITDA	8.9	7.4	6.2
Current op. Margin (%)	13.6	15.1	17.5	18.4	EV/EBIT	15.4	11.9	9.8
EPS (€)	0.00	0.17	0.20	0.23	PE	24.1	20.7	17.9
DPS (€)	0.00	0.00	0.00	0.00	Source: TPICAP Midcap			
Yield (%)	0.0	0.0	0.0	0.0				
FCF (m €)	1.6	-0.9	-0.5	3.4				

Equity Strategist

 Sarah Thirion
 sarah.thirion@tpicap.com
 +33153451072


Analyst

 Alessio Olmi
 alessio.olmi@tpicap.com
 +33149241801


Key data

Price (€)	4.2
Industry	Tourism
Ticker	ALKLN-FR
Shares Out (m)	14.125
Market Cap (m €)	59.1
Next event	FY 2025 - 30.03.2026

Source: FactSet

Ownership (%)


L6A4 S.r.l. (Vitaliano Borromeo)	68.7
Free float	31.3

Source: TPICAP Midcap estimates

EPS (€)	12/25e	12/26e	12/27e
Estimates	0.17	0.20	0.23
Change vs previous estimates (%)	na	na	na

Source: TPICAP Midcap estimates

Performance (%)	1D	1M	YTD
Price Perf	0.1	1.5	3.5
Rel FTSE Italy	0.1	2.9	3.1



Source: FactSet

Consensus FactSet - Analysts:2	12/25e	12/26e	12/27e
Sales	23.1	25.5	27.8
EBIT	3.5	4.2	4.8
Net income	2.5	2.7	3.0

FINANCIAL DATA

Income Statement	12/22	12/23	12/24	12/25e	12/26e	12/27e
Sales	0.0	21.5	21.7	23.2	26.1	28.6
Changes (%)	na	na	0.7	7.0	12.6	9.6
Gross profit	0.0	20.1	20.5	21.7	24.5	26.8
% of Sales	na	93.3	94.6	93.6	93.7	93.7
EBITDA	0.0	6.7	5.5	6.1	7.4	8.3
% of Sales	na	31.3	25.4	26.1	28.3	29.0
Current operating profit	0.0	4.4	2.9	3.5	4.6	5.3
% of Sales	na	20.7	13.6	15.1	17.5	18.4
Non-recurring items	0.0	-0.0	-0.0	0.0	0.0	0.0
EBIT	0.0	4.4	2.9	3.5	4.6	5.3
Net financial result	0.0	-0.2	-0.2	-0.2	-0.2	-0.2
Income Tax	0.0	-1.3	-1.2	-1.3	-1.5	-1.8
Tax rate (%)	0.0	-31.7	-43.6	-35.0	-35.0	-35.0
Net profit, group share	0.0	2.9	1.5	2.5	2.9	3.3
EPS	na	na	na	0.17	0.20	0.23
Financial Statement	12/22	12/23	12/24	12/25e	12/26e	12/27e
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0
Tangible and intangible assets	0.0	20.2	22.6	24.8	28.1	27.8
Right of Use	0.0	0.0	0.0	0.0	0.0	0.0
Financial assets	0.0	0.1	0.1	0.7	0.7	0.7
Working capital	0.0	-0.5	-2.5	-2.2	-1.9	-1.5
Other Assets	0.0	0.0	0.0	0.0	0.0	0.0
Assets	0.0	19.9	20.3	23.3	26.9	27.0
Shareholders equity group	0.0	4.7	6.2	27.2	30.0	33.3
Minorities	0.0	0.0	0.0	0.0	0.0	0.0
LT & ST provisions and others	0.0	1.2	1.3	1.3	1.3	1.3
Net debt	0.0	13.9	12.7	-5.2	-4.5	-7.7
Other liabilities	0.0	0.0	0.0	0.0	0.0	0.0
Liabilities	0.0	19.9	20.3	23.3	26.9	27.0
Net debt excl. IFRS 16	0.0	13.9	12.7	-5.2	-4.5	-7.7
Gearing net	na	3.0	2.0	-0.2	-0.1	-0.2
Leverage	na	2.1	2.3	-0.9	-0.6	-0.9
Cash flow statement	12/22	12/23	12/24	12/25e	12/26e	12/27e
CF after elimination of net borrowing costs and taxes	0.0	0.0	4.9	4.7	5.8	6.5
ΔWCR	0.0	0.0	1.5	-0.3	-0.2	-0.4
Operating cash flow	0.0	0.0	6.4	4.4	5.6	6.1
Net capex	0.0	0.0	-4.8	-5.3	-6.1	-2.7
FCF	0.0	0.0	1.6	-0.9	-0.5	3.4
Acquisitions/Disposals of subsidiaries	0.0	0.0	0.0	0.0	0.0	0.0
Other investments	0.0	0.0	0.0	0.0	0.0	0.0
Change in borrowings	0.0	0.0	-1.2	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0
Repayment of leasing debt	0.0	0.0	0.0	0.0	0.0	0.0
Equity Transaction	0.0	0.0	0.0	16.5	0.0	0.0
Others	0.0	0.0	-0.2	0.0	0.5	0.0
Change in net cash over the year	0.0	0.0	0.0	15.5	-0.2	3.2
ROA (%)	na	14.6%	7.6%	10.5%	10.6%	12.3%
ROE (%)	na	61.6%	24.7%	9.0%	9.5%	9.9%
ROCE (%)	na	15.2%	8.0%	9.5%	10.8%	12.5%

DISCLAIMER

Analyst certifications

This research report (the “Report”) has been approved by Midcap, a business division of TP ICAP (Europe) SA (“Midcap”), an Investment Services Provider authorised and regulated by the Autorité de Contrôle Prudentiel et de Résolution (“ACPR”). By issuing this Report, each Midcap analyst and associate whose name appears within this Report hereby certifies that (i) the recommendations and opinions expressed in the Report accurately reflect the research analyst’s and associate’s personal views about any and all of the subject securities or issuers discussed herein and (ii) no part of the research analyst’s or associate’s compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst or associate in the Report.

Methodology

This Report may mention evaluation methods defined as follows:

1. DCF method: discounting of future cash flows generated by the company's operations. Cash flows are determined by the analyst's financial forecasts and models. The discount rate used corresponds to the weighted average cost of capital, which is defined as the weighted average cost of the company's debt and the theoretical cost of its equity as estimated by the analyst.
2. Comparable method: application of market valuation multiples or those observed in recent transactions. These multiples can be used as references and applied to the company's financial aggregates to deduce its valuation. The sample is selected by the analyst based on the characteristics of the company (size, growth, profitability, etc.). The analyst may also apply a premium/discount depending on his perception of the company's characteristics.
3. Assets and liabilities method: estimate of the value of equity capital based on revalued assets adjusted for the value of the debt.
4. Discounted dividend method: discounting of estimated future dividend flows. The discount rate used is generally the cost of capital.
5. Sum of the parts: this method consists of estimating the various activities of a company using the most appropriate valuation method for each of them, then realizing the sum of the parts.

Conflict of Interests between TP ICAP Midcap and the Issuer

- D. Midcap or any related legal entity is a market maker or liquidity provider with whom a liquidity agreement has been entered into in respect of the Issuer's financial instruments: Kaleon
- E. Midcap or any related legal entity has acted, over the last twelve months, as lead or co-lead in a public offer for financial instruments of the Issuer: Kaleon
- F. Midcap or any legal entity related to it is party to any other agreement with the Issuer relating to the provision of investment services in connection with the corporate activity: Kaleon
- G. Midcap and the Issuer have agreed to the provision by the former to the latter of a service for the production and distribution of the investment recommendation on the said Issuer: Kaleon

History of investment rating and target price – Kaleon

Historical recommendations and target price (-1Y)

Date	Analyst	Old Target Price	New Target Price	Closing Price	Old Recommendation	New Recommendation
09 Feb 26 - 08:19:44	Alessio Olmi	NA	€ 5.50	€ 4.08	NA	Buy

Distribution of Investment Ratings

Rating	Recommendation Universe*	Portion of these provided with investment banking services**
Buy	74%	71%
Hold	19%	60%
Sell	4%	33%
Under review	4%	100%

Midcap employs a rating system based on the following:

Buy: Expected to outperform the markets by 10% or more over a 6 to 12 months horizon.

Hold: expected performance between -10% and +10% compared to the market over a 6 to 12 months horizon.

Sell: Stock is expected underperform the markets by 10% or more over a 6 to 12 months horizon.

The history of ratings and target prices for the Issuers covered in this report are available on request at <https://researchtpicap.midcapp.com/en/disclaimer>.

General Disclaimer

This Report is confidential and is for the benefit and internal use of the selected recipients only. No part of it may be reproduced, distributed, or transmitted without the prior written consent of Midcap

This Report is published for information purposes only and does not constitute a solicitation or an offer to buy or sell any of the securities mentioned herein. The information contained in this Report has been obtained from sources believed to be reliable and public, Midcap makes no representation as to its accuracy or completeness. The reference prices used in this Report are closing prices of the day before the publication unless otherwise stated. All opinions expressed in this Report reflect our judgement at the date of the documents and are subject to change without notice. The securities discussed in this Report may not be suitable for all investors and are not intended to recommend specific securities, financial instruments, or strategies to particular clients. Investors should make their own investment decisions based on their financial situation and investment objectives. The value of the income from your investment may vary due to changes in interest rates, changes in the financial and operating conditions of companies and other factors. Investors should be aware that the market price of the securities discussed in this Report may be volatile. Due to the risk and volatility of the industry, the company, and the market in general, at the current price of the securities, our investment rating may not correspond to the stated price target. Additional information regarding the securities mentioned in this Report is available on request.

This Report is not intended for distribution or use by any entity who is a citizen or resident of, or an entity located in any locality, territory, state, country, or other jurisdiction where such distribution, publication, availability, or use would be contrary to or limited by law or regulation. Entity or entities in possession of this Report must inform themselves about and comply with any such restrictions, including MIFID II. This Report is only intended for persons who are Eligible Counterparties or Professional Clients within the meaning of MIFID II regulation. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. The Report is subject to restricted circulation. The research was conducted in accordance with the provisions of the Charter of good practices for sponsored research. Midcap has adopted effective administrative and organizational arrangements, including "information barriers", to prevent and avoid conflicts of interest regarding investment recommendations. The remuneration of financial analysts who participate in the preparation of the recommendation is not linked to the corporate finance activity.

The company may provide corporate access services, which notably include the organization of meetings, conferences or discussions between investors and issuers. These services are separate from the research activity and have no influence on the content, quality or objectivity of the analyses presented in this document. The opinions expressed are based exclusively on sources believed to be reliable and on the author's own analysis, independently of any commercial relationship or issuer access arrangements. No part of the author's or associate's compensation was, is or will be directly or indirectly related to commercial relationships or issuer access arrangements.

Corporate access services are provided in compliance with the applicable regulatory requirements.